Donanemab marks a significant advancement in Alzheimer’s treatment, but NHS patients face a setback with NICE's rejection of ...

The Boston-based biotech will use the new fundraise to develop its pipeline of drug candidates for conditions such as major ...

The acquisition will add a late-stage drug candidate with blockbuster potential to Lundbeck’s neuroscience pipeline.

Investors and big pharma companies are waking up to the potential of techbio companies after years of avoidance, say experts ...

The FDA decision will enable Antag Therapeutics to initiate the clinical development of its lead candidate drug, a ...

As active pharmaceutical ingredients (APIs) and medicines become more complex and the demand for efficiency rises, drug ...

Jane Koo, head of regulatory affairs at CTMC, plays an important role in accelerating the development and commercialization ...

From exploring the wonders of plants as a curious teen to leading global initiatives at SCIEX, Gitte Barknowitz has carved ...

Evaxion’s proprietary AI-Immunology platform has shown in clinical trials that it can select clinically relevant cancer ...

At the forefront of precision dosing, Sharmeen leads DoseMe's efforts to transform personalized medicine from lab research to ...

The big pharma company Sanofi has discontinued a phase 2 trial of U.S. partner Denali Therapeutics’ oditrasertib for the treatment of multiple sclerosis after the drug failed to perform.